vida: extract claims from 2026-04-22-kff-employer-glp1-survey-2025-paradox-large-employer-coverage

- Source: inbox/queue/2026-04-22-kff-employer-glp1-survey-2025-paradox-large-employer-coverage.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift.md

@@ -31,3 +31,10 @@ The behavioral mandate acceleration (34% of employers requiring support, up from
 **Source:** PHTI December 2025 Employer GLP-1 Approaches Report + Mercer 2026
 
 PHTI December 2025 report confirms 34% of employers requiring behavioral support as GLP-1 coverage condition (up from 10% — 3.4x in one year). Critical scope qualification: this applies to LARGE employers (500+ employees or self-insured) who have already chosen to cover GLP-1s. Survey methodology covers employer-sponsored plans with sufficient scale to administer condition-based coverage. Mercer 2026 data shows 90% of large employers plan to continue GLP-1 coverage through 2026, 86% of mid-market employers continuing. The behavioral mandate represents cost management within continuing coverage, not coverage elimination.
+
+
+## Supporting Evidence
+
+**Source:** Mercer Survey on Health & Benefits Strategies for 2026
+
+Mercer 2026 survey documents that large employers maintaining GLP-1 coverage are implementing 'behavioral conditions, quantity limits, specialized care management programs' as cost management approaches. This confirms the shift from open formulary access to managed access infrastructure, consistent with the behavioral mandate tripling documented elsewhere.

domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md

@@ -39,3 +39,10 @@ Scope resolution: the 3.6M → 2.8M covered lives decline (22% reduction) applie
 **Source:** National Law Review, FDA April 1 2026 clarification
 
 The FDA's April 2026 clarification targeted combination formulations (semaglutide + vitamin B12) that compounders used to escape the 'essentially a copy' standard, signaling regulatory skepticism. The 503A safe harbor requires individualized clinical justification from prescribers demonstrating 'significant difference' for each patient, with boilerplate clinical rationale deemed insufficient. This creates additional administrative burden that further constrains the compounding access pathway even within the 4 Rx/month limit.
+
+
+## Supporting Evidence
+
+**Source:** KFF 2025, Mercer 2026, DistilINFO via NPR
+
+Reconciliation of apparent contradiction: KFF shows 49% large employer coverage (up from 44%), Mercer shows 90% large employer retention, yet DistilINFO confirms 22% decline in total covered lives. The resolution: large employers (500+) are stable/expanding while smaller employers, health systems, state plans, and regional payers withdraw coverage. The net effect is population-level coverage decline despite large-employer stability. This confirms the bifurcation pattern where employer size predicts coverage persistence.

inbox/archive/health/2026-04-22-kff-employer-glp1-survey-2025-paradox-large-employer-coverage.md

@@ -7,10 +7,13 @@ date: 2026-04-22
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-01
 priority: medium
 tags: [GLP-1, employer-coverage, KFF, Mercer, survey-methodology, covered-lives, obesity-management]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content